Search
Descriptor English: Zidovudine
Descriptor Spanish: Zidovudina
Descriptor zidovudina
Entry term(s) AZT (antiviral)
azidotimidina
Scope note: Compuesto didesoxinucleósido en el cual el grupo 3'-hidroxilo de la molécula de azúcar se ha reemplazado por un grupo azida. Esta modificación impide la formación de los enlaces fosfodiéster necesarios para completar las cadenas de ácidos nucleicos. El compuesto es un inhibidor potente de la replicación del VIH, y actúa como terminador de la cadena del ADN viral durante la transcripción inversa. Mejora la función inmunológica, revierte parcialmente la disfunción neurológica inducida por el VIH, y mejora otras anomalías clínicas asociadas con el SIDA. Su principal efecto tóxico es la depresión de la médula ósea, dependiente de la dosis, que produce anemia y leucopenia.
Descriptor Portuguese: Zidovudina
Descriptor French: Zidovudine
Entry term(s): 3' Azido 2',3' Dideoxythymidine
3' Azido 3' deoxythymidine
3'-Azido-2',3'-Dideoxythymidine
3'-Azido-3'-deoxythymidine
AZT (Antiviral)
AZT Antiviral
AZT, Antiviral
Antiviral AZT
Azidothymidine
BW A509U
BWA 509U
BWA-509U
BWA509U
Retrovir
Tree number(s): D03.383.742.680.705.950
D13.570.230.500.950
D13.570.230.855.950
D13.570.685.705.950
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D015215
Scope note: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.
Allowable Qualifiers: AA analogs & derivatives
AD administration & dosage
AE adverse effects
AG agonists
AI antagonists & inhibitors
AN analysis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
CS chemical synthesis
EC economics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PK pharmacokinetics
PO poisoning
RE radiation effects
SD supply & distribution
ST standards
TO toxicity
TU therapeutic use
UR urine
Pharm Action: Antimetabolites
Reverse Transcriptase Inhibitors
Anti-HIV Agents
Registry Number: 4B9XT59T7S
CAS Type 1 Name: Thymidine, 3'-azido-3'-deoxy-
Previous Indexing: Thymidine/analogs & derivatives (1975-1988)
Public MeSH Note: 89
History Note: 89
DeCS ID: 23867
Unique ID: D015215
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 1989/01/01
Date of Entry: 1988/05/09
Revision Date: 2016/06/01
Zidovudine - Preferred
Concept UI M0023377
Scope note A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.
Preferred term Zidovudine
Entry term(s) 3' Azido 2',3' Dideoxythymidine
3' Azido 3' deoxythymidine
3'-Azido-2',3'-Dideoxythymidine
3'-Azido-3'-deoxythymidine
AZT (Antiviral)
AZT Antiviral
AZT, Antiviral
Antiviral AZT
Azidothymidine
Retrovir - Related but not broader or narrower
Concept UI M0023378
Preferred term Retrovir
BW A509U - Narrower
Concept UI M0373894
Preferred term BW A509U
Entry term(s) BWA 509U
BWA-509U
BWA509U



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.

Go to survey